Content about Lou Gehrig

June 11, 2013

Aceto Corp. will sell an authorized generic version of a drug used to treat a rare but devastating degenerative disorder.

PORT WASHINGTON, N.Y. — Aceto Corp. will sell an authorized generic version of a drug used to treat a rare but devastating degenerative disorder.

Aceto said it would launch the authorized generic version of Covis Pharma's Rilutek (riluzole) tablets in the 50-mg strength through its Rising Pharmaceuticals subsidiary. The drug is used to treat amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

Sales of the drug were about $64 million in 2012, according to Aceto.

 

May 10, 2013

A biotech company and a non-profit organization are looking into new ways to treat patients with the devastating degenerative disorder commonly known as Lou Gehrig's disease.

SAN DIEGO — A biotech company and a nonprofit organization are looking into new ways to treat patients with the devastating degenerative disorder commonly known as Lou Gehrig's disease.

The ALS Emergency Treatment Fund and Denovo Biomarkers announced Friday a deal to explore the use of personalized medicine in treating patients with the disease, known medically as amyotrophic lateral sclerosis. The two said the approach could accelerate drug development in ALS and other life-threatening disorders.

April 4, 2013

Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said.

ZUG, Switzerland — Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said Thursday.

January 3, 2013

An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said.

WESTON, Mass. — An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said Thursday.

Biogen announced results of its phase-3 trial of dexpramipexole in patients with the disease, known technically as amyotrophic lateral sclerosis, or ALS. The drug failed to improve functioning and survival in patients and failed to show efficacy in key secondary endpoints as well, the company said.

August 29, 2012

In the battle to find a cure for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, scientists from Belgium have made a rare discovery: a new gene that influences survival time of ALS. The findings, reported in a recent issue of Nature Medicine, were funded in part by CVS/pharmacy and the ALS Therapy Alliance, a Boston-based nonprofit.

NEEDHAM, Mass. — In the battle to find a cure for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, scientists from Belgium have made a rare discovery: a new gene that influences survival time of ALS. The findings, reported in a recent issue of Nature Medicine, were funded in part by CVS/pharmacy and the ALS Therapy Alliance, a Boston-based nonprofit. The findings also confirm another recent study that identified the same pathway to finding a treatment for ALS.

August 18, 2010

Swiss drug maker Biogen Idec will develop and commercialize an investigational drug as a treatment...

May 16, 2010

An investigational drug made by Teva Pharmaceutical Industries was not effective in patients with Lou...